From pipeline to launch—make faster, smarter decisions.
Breast Cancer
Ovarian Cancer
Launch Planning
Launch Sequence Planning
Plan ahead with visibility into competitive timelines
Competitive Threat Assessment
High
Med
Low
Low
None
None
Trial
Phase
Competition
HALMONi-9a
HALMONi-2
HALMONi-6
HALMONi-1
HALMONi-5
HALMONi
3
3
3
3
3
3
Miraei Virtuoso Insight
HALMONi-9a
Ivonescimab + chemo vs.chemo
Competes directly in 2L NSCLC post-PD-1/L1 failure. True head-to-head threat.
Strategic Planning
Detect threats—and the moves behind them
Pre-Clin
P1
P2
P3
Status
Design
Indication
Biomarkers
Ongoing, global Phase 3
Randomized, controlled vs docetaxel
NSCLC, CPI-refractory, PD-L1+
PD-L1, VEGF-A enriched (exploratory)
Geographies
Milestones
ORR
PFS
OS
Safety
38% (Phase 2)
6.2 mo vs 4.5 mo (docetaxel control)
Unknown
Elevated VEGF-related AEs
Primary
Global
China
U.S., EU sites recruiting underway
Ivonescimal (AK112) Lead Program
Results
Trial
Competitor Deep-Dive
Get a 360° view of any competitor program